STOCK TITAN

Starling Oncology CEO Virnich sells 5,102 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Starling Oncology, Inc. Chief Executive Officer Daniel Virnich reported a disposition of 5,102 common shares on November 17, 2026, at $3.40 per share. The issuer-mandated sell-to-cover transaction satisfied tax withholding obligations connected with restricted stock unit vesting and was not a discretionary trade. His reported direct holdings after the transaction were 2,332,064 shares.

Insider Virnich Daniel
Role Chief Executive Officer
Type Security Shares Price Value
Other Common Stock F1 5,102 $3.40 $17K
Holdings After Transaction: Common Stock — 2,332,064 shares (Direct)
Footnotes (1)
  1. F1. Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person.
Common shares disposed 5,102 shares November 17, 2026; sell-to-cover transaction for tax withholding obligations
Transaction price $3.40 per share November 17, 2026 transaction
Direct holdings after transaction 2,332,064 shares Daniel Virnich's reported holdings following the transaction
sell-to-cover transaction financial
"sell-to-cover transaction in satisfaction of tax withholding obligations"
A sell-to-cover transaction is when a person granted company stock (for example as part of compensation or option exercise) immediately sells enough of those shares to pay required taxes or exercise costs and keeps the rest. Think of it like cashing part of a bonus to cover the tax bill; it provides necessary cash without the holder needing outside funds. Investors watch these sales because they increase trading volume and slightly reduce insider holdings, but they often reflect routine tax or cost management rather than a judgment on the company’s prospects.
restricted stock units financial
"vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Starling Oncology CEO Daniel Virnich dispose of?

Daniel Virnich reported a disposition of 5,102 common shares on November 17, 2026, at $3.40 per share; his reported direct holdings afterward were 2,332,064 shares.

Why did Daniel Virnich's STLN share transaction occur?

The shares were required to be sold in an issuer-mandated sell-to-cover transaction to satisfy tax withholding obligations connected with restricted stock unit vesting; the footnote says it was not a discretionary trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Virnich Daniel

(Last)(First)(Middle)
C/O STARLING ONCOLOGY, INC.
18000 STUDEBAKER RD, SUITE 800

(Street)
CERRITOS CALIFORNIA 90703

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Starling Oncology, Inc. [ STLN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026J(1)5,102D$3.42,332,064D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person.
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading